24-10-2013 дата публикации
Номер: US20130281714A1
The present invention relates to a macrolide compound expected to have a cell growth-inhibiting activity and a novel anticancer drug utilizing the compound. Specifically, the invention relates to a compound represented by Formula (I) or (II) or a pharmaceutically acceptable salt thereof and relates to a cell growth inhibitor and an anticancer drug each containing the compound or the salt as an active ingredient. 2. A cell growth inhibitor comprising the compound or a pharmaceutically acceptable salt thereof according to .3. The cell growth inhibitor according to claim 2 , wherein the inhibitor inhibits the growth of cancer cells.4. The cell growth inhibitor according to claim 3 , wherein the cancer is selected from the group consisting of pancreatic cancer claim 3 , colon cancer claim 3 , liver cancer claim 3 , brain cancer claim 3 , lung cancer claim 3 , squamous cell carcinoma claim 3 , bladder cancer claim 3 , gastric cancer claim 3 , pancreatic cancer claim 3 , prostatic cancer claim 3 , kidney cancer claim 3 , colorectal cancer claim 3 , breast cancer claim 3 , head cancer claim 3 , neck cancer claim 3 , esophageal cancer claim 3 , gynecological cancer claim 3 , thyroid cancer claim 3 , lymphoma claim 3 , chronic leukemia claim 3 , and acute leukemia.5. The cell growth inhibitor according to claim 3 , wherein the cancer is lung cancer.6. An anticancer drug comprising the compound or a pharmaceutically acceptable salt thereof according to .7. The anticancer drug according to claim 6 , wherein the cancer is selected from the group consisting of pancreatic cancer claim 6 , colon cancer claim 6 , liver cancer claim 6 , brain cancer claim 6 , lung cancer claim 6 , squamous cell carcinoma claim 6 , bladder cancer claim 6 , gastric cancer claim 6 , pancreatic cancer claim 6 , prostatic cancer claim 6 , kidney cancer claim 6 , colorectal cancer claim 6 , breast cancer claim 6 , head cancer claim 6 , neck cancer claim 6 , esophageal cancer claim 6 , gynecological cancer ...
Подробнее